Resminostat

From WikiMD.org
Jump to navigation Jump to search

Resminostat (pronounced as rez-min-o-stat) is a histone deacetylase inhibitor (HDAC inhibitor) that is primarily used in the treatment of cancer. It is an experimental drug that is currently under clinical trials.

Etymology

The term "Resminostat" is derived from the words "resistance" and "minostat". The "res" in Resminostat refers to the drug's ability to resist the growth of cancer cells, while "minostat" is a common suffix used in the names of HDAC inhibitors.

Pharmacology

Resminostat works by inhibiting the activity of histone deacetylases, a group of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone. This allows the histones to wrap the DNA more tightly. By inhibiting these enzymes, Resminostat helps to stop the growth of cancer cells.

Clinical Trials

Resminostat has been tested in several clinical trials for its effectiveness in treating various types of cancer, including hepatocellular carcinoma, Hodgkin's lymphoma, and non-small cell lung cancer. The results of these trials have shown promise, but further research is needed to confirm the drug's effectiveness and safety.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski